Preliminary evidence suggests that use of GLP-1 agonists such semaglutide or GLP-1 dual agonists such as tirzepatide to treat type 2 diabetes or for weight loss do not increase the risk of breast cancer
Regul Pept 93:45-51 2000 Perfetti R, Merkel P
One year after Lund and Goodman made their unexpected finding, another team successfully isolated and sequenced the pancreatic preproglucagon from a hamster islet library
Visible fat loss on the scale: 4-12 weeks typically
Meta-analyses of randomised controlled trials have demonstrated mean increases of approximately 24 beats per minute, with variation depending on the specific agent, dose, and patient population
Nagamatsu M, Nickander KK, Schmelzer JD, et al